Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Corp. (Lexaria Bioscience Corp.) on September 28, 2012. The report discloses the entry into a material definitive agreement regarding the grant of stock options and unregistered sales of equity securities under the company's 2010 Stock Option Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate action rather than periodic financial performance.
Material Changes and Corporate Actions
- Stock Option Grant: On September 28, 2012, the Company granted 25,000 additional stock options to Directors and Officers.
- Recipient: All 25,000 options were granted to Lona Coates.
- Terms: The exercise price is US$0.20 per share. The options vest immediately and expire on September 28, 2017.
- Regulatory Disclosure: The filing includes a Regulation FD disclosure referencing a press release regarding an appointment (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of the option grant terms.
Investor Verification Checklist
- Verify the total number of outstanding options under the 2010 Stock Option Plan post-grant.
- Confirm the identity and role of Lona Coates within the company.
- Review the full text of the press release (Exhibit 99.1) to understand the context of the "appointment" mentioned in Item 7.01.
- Check subsequent filings for any dilution impact on existing shareholders.